Free Trial

Danaher Corporation (NYSE:DHR) Shares Sold by WealthPlan Investment Management LLC

Danaher logo with Medical background

Key Points

  • WealthPlan Investment Management LLC has decreased its stake in Danaher Corporation by 21.3%, owning 20,219 shares worth approximately $4.15 million after selling 5,469 shares in the first quarter.
  • Danaher Corporation's Chairman, Steven M. Rales, recently sold 1.25 million shares of the company's stock for about $245.93 million, resulting in a 28.7% decrease in his ownership.
  • Analysts have mixed views on Danaher, with Goldman Sachs lowering its target price from $260 to $240, while others, like Scotiabank, have raised their rating and set a new price target of $275.
  • Need Better Tools to Track Danaher? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

WealthPlan Investment Management LLC lowered its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 21.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,219 shares of the conglomerate's stock after selling 5,469 shares during the quarter. WealthPlan Investment Management LLC's holdings in Danaher were worth $4,145,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. FAS Wealth Partners Inc. increased its stake in shares of Danaher by 20.6% during the 4th quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock valued at $2,203,000 after acquiring an additional 1,639 shares during the last quarter. MGO One Seven LLC increased its stake in shares of Danaher by 485.7% during the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock valued at $5,145,000 after acquiring an additional 20,813 shares during the last quarter. Asahi Life Asset Management CO. LTD. acquired a new position in shares of Danaher during the 1st quarter valued at about $539,000. Horizon Financial Services LLC increased its stake in shares of Danaher by 20,400.0% during the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock valued at $1,681,000 after acquiring an additional 8,160 shares during the last quarter. Finally, Vision Capital Management Inc. acquired a new position in shares of Danaher during the 1st quarter valued at about $461,000. Institutional investors and hedge funds own 79.05% of the company's stock.

Insider Transactions at Danaher

In related news, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman directly owned 3,105,808 shares in the company, valued at $611,036,665.92. This trade represents a 28.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 11.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. The Goldman Sachs Group dropped their target price on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Wall Street Zen raised shares of Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Leerink Partners upped their price target on shares of Danaher from $225.00 to $230.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 23rd. Finally, Scotiabank raised shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target for the company in a research report on Friday, July 11th. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $247.61.

Check Out Our Latest Report on DHR

Danaher Stock Performance

Danaher stock opened at $195.34 on Thursday. The stock has a market cap of $139.87 billion, a P/E ratio of 41.56, a price-to-earnings-growth ratio of 2.77 and a beta of 0.73. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The stock has a 50 day moving average of $198.08 and a 200-day moving average of $201.81. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The business's revenue was up 3.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.72 EPS. On average, analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

About Danaher

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Read More

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Danaher Right Now?

Before you consider Danaher, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.

While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Quantum Boom: 3 Strong Picks with Lower Risk
3 Overlooked AI Stocks That Chipmakers Can’t Live Without
Palantir & AMD Earnings: Massive Options Setups Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines